TrialHuman vaccines & immunotherapeutics2023

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults.

Patrick Yassini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.